SymBio Pharmaceuticals Limited (4582.T)
JPY 154.0
(0.65%)
JPY 154.0
(0.65%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 5.58 Billion JPY | -44.15% |
| 2022 | 10 Billion JPY | 21.28% |
| 2021 | 8.25 Billion JPY | 176.28% |
| 2020 | 2.98 Billion JPY | 5.26% |
| 2019 | 2.83 Billion JPY | -26.01% |
| 2018 | 3.83 Billion JPY | 11.36% |
| 2017 | 3.44 Billion JPY | 45.44% |
| 2016 | 2.36 Billion JPY | 22.49% |
| 2015 | 1.93 Billion JPY | -1.11% |
| 2014 | 1.95 Billion JPY | 27.61% |
| 2013 | 1.53 Billion JPY | -21.64% |
| 2012 | 1.95 Billion JPY | 3.86% |
| 2011 | 1.88 Billion JPY | 29.83% |
| 2010 | 1.44 Billion JPY | 21.73% |
| 2009 | 1.19 Billion JPY | -26.93% |
| 2008 | 1.63 Billion JPY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 597.86 Million JPY | -48.84% |
| 2024 Q3 | 613.94 Million JPY | -10.58% |
| 2024 Q2 | 686.56 Million JPY | 14.84% |
| 2023 Q4 | 1.16 Billion JPY | -5.94% |
| 2023 Q1 | 1.54 Billion JPY | -41.77% |
| 2023 FY | 5.58 Billion JPY | -44.15% |
| 2023 Q2 | 1.63 Billion JPY | 5.76% |
| 2023 Q3 | 1.24 Billion JPY | -23.96% |
| 2022 Q4 | 2.65 Billion JPY | 6.89% |
| 2022 FY | 10 Billion JPY | 21.28% |
| 2022 Q1 | 2.31 Billion JPY | -14.21% |
| 2022 Q2 | 2.55 Billion JPY | 10.44% |
| 2022 Q3 | 2.48 Billion JPY | -2.97% |
| 2021 Q3 | 2.4 Billion JPY | 39.4% |
| 2021 Q1 | 1.42 Billion JPY | 117.03% |
| 2021 FY | 8.25 Billion JPY | 176.28% |
| 2021 Q4 | 2.69 Billion JPY | 12.18% |
| 2021 Q2 | 1.72 Billion JPY | 21.54% |
| 2020 FY | 2.98 Billion JPY | 5.26% |
| 2020 Q2 | 809.27 Million JPY | 46.78% |
| 2020 Q1 | 551.36 Million JPY | -33.55% |
| 2020 Q3 | 971.95 Million JPY | 20.1% |
| 2020 Q4 | 654.45 Million JPY | -32.67% |
| 2019 Q3 | 3.07 Million JPY | -99.22% |
| 2019 Q2 | 393.51 Million JPY | -75.58% |
| 2019 FY | 2.83 Billion JPY | -26.01% |
| 2019 Q4 | 829.7 Million JPY | 26908.63% |
| 2019 Q1 | 1.61 Billion JPY | 100.64% |
| 2018 Q4 | 803.16 Million JPY | -27.25% |
| 2018 FY | 3.83 Billion JPY | 11.36% |
| 2018 Q1 | 888.22 Million JPY | -13.56% |
| 2018 Q2 | 1.04 Billion JPY | 17.1% |
| 2018 Q3 | 1.1 Billion JPY | 6.14% |
| 2017 Q3 | 630.62 Million JPY | -31.18% |
| 2017 FY | 3.44 Billion JPY | 45.44% |
| 2017 Q1 | 869.61 Million JPY | -9.46% |
| 2017 Q2 | 916.39 Million JPY | 5.38% |
| 2017 Q4 | 1.02 Billion JPY | 62.95% |
| 2016 FY | 2.36 Billion JPY | 22.49% |
| 2016 Q4 | 960.49 Million JPY | 387.84% |
| 2016 Q1 | 193.18 Million JPY | -67.85% |
| 2016 Q2 | 1.01 Billion JPY | 426.72% |
| 2016 Q3 | 196.88 Million JPY | -80.65% |
| 2015 Q1 | 408.22 Million JPY | -32.73% |
| 2015 Q3 | 356.19 Million JPY | -37.29% |
| 2015 FY | 1.93 Billion JPY | -1.11% |
| 2015 Q4 | 600.85 Million JPY | 68.69% |
| 2015 Q2 | 567.97 Million JPY | 39.13% |
| 2014 Q3 | 372.86 Million JPY | -53.49% |
| 2014 FY | 1.95 Billion JPY | 27.61% |
| 2014 Q4 | 606.82 Million JPY | 62.75% |
| 2014 Q2 | 801.66 Million JPY | 361.57% |
| 2014 Q1 | 173.68 Million JPY | -16.7% |
| 2013 Q2 | 321.79 Million JPY | -34.2% |
| 2013 Q3 | 512.73 Million JPY | 59.34% |
| 2013 Q4 | 208.51 Million JPY | -59.33% |
| 2013 FY | 1.53 Billion JPY | -21.64% |
| 2013 Q1 | 489.01 Million JPY | 11.97% |
| 2012 Q3 | 464.14 Million JPY | -1.97% |
| 2012 Q4 | 436.73 Million JPY | -5.91% |
| 2012 FY | 1.95 Billion JPY | 3.86% |
| 2012 Q1 | 580.81 Million JPY | 0.9% |
| 2012 Q2 | 473.48 Million JPY | -18.48% |
| 2011 Q1 | 348.1 Million JPY | 0.0% |
| 2011 Q2 | 634.54 Million JPY | 82.29% |
| 2011 Q3 | 324.24 Million JPY | -48.9% |
| 2011 Q4 | 575.62 Million JPY | 77.53% |
| 2011 FY | 1.88 Billion JPY | 29.83% |
| 2010 Q4 | - JPY | 0.0% |
| 2010 Q2 | - JPY | 0.0% |
| 2010 FY | 1.44 Billion JPY | 21.73% |
| 2009 Q4 | - JPY | 0.0% |
| 2009 FY | 1.19 Billion JPY | -26.93% |
| 2008 FY | 1.63 Billion JPY | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 62.14 Billion JPY | 91.006% |
| Takeda Pharmaceutical Company Limited | 4263.76 Billion JPY | 99.869% |
| Sumitomo Pharma Co., Ltd. | 314.55 Billion JPY | 98.223% |
| Shionogi & Co., Ltd. | 435.08 Billion JPY | 98.715% |
| Wakamoto Pharmaceutical Co.,Ltd. | 7.73 Billion JPY | 27.767% |
| Nippon Shinyaku Co., Ltd. | 148.25 Billion JPY | 96.23% |
| Kaken Pharmaceutical Co., Ltd. | 72.04 Billion JPY | 92.241% |
| Eisai Co., Ltd. | 741.75 Billion JPY | 99.246% |
| Morishita Jintan Co., Ltd. | 12.4 Billion JPY | 54.944% |
| Hisamitsu Pharmaceutical Co., Inc. | 141.7 Billion JPY | 96.055% |
| Mochida Pharmaceutical Co., Ltd. | 102.88 Billion JPY | 94.567% |
| Fuso Pharmaceutical Industries,Ltd. | 55.4 Billion JPY | 89.911% |
| Nippon Chemiphar Co., Ltd. | 30.74 Billion JPY | 81.821% |
| Tsumura & Co. | 150.84 Billion JPY | 96.294% |
| Kissei Pharmaceutical Co., Ltd. | 75.57 Billion JPY | 92.604% |
| Torii Pharmaceutical Co., Ltd. | 54.63 Billion JPY | 89.77% |
| Towa Pharmaceutical Co., Ltd. | 227.93 Billion JPY | 97.548% |
| Fuji Pharma Co., Ltd. | 40.88 Billion JPY | 86.33% |
| Zeria Pharmaceutical Co., Ltd. | 75.72 Billion JPY | 92.618% |
| KYORIN Holdings, Inc. | 119.53 Billion JPY | 95.324% |
| Taiko Pharmaceutical Co.,Ltd. | 5.04 Billion JPY | -10.907% |
| Daito Pharmaceutical Co.,Ltd. | 46.89 Billion JPY | 88.08% |
| MedRx Co., Ltd | 26 Million JPY | -21398.877% |
| Mizuho Medy Co.,Ltd. | 10.98 Billion JPY | 49.137% |
| Solasia Pharma K.K. | 617 Million JPY | -805.949% |
| Modalis Therapeutics Corporation | - JPY | -Infinity% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | 62.84 Billion JPY | 91.105% |
| Sawai Group Holdings Co., Ltd. | 176.86 Billion JPY | 96.84% |
| Cyfuse Biomedical K.K. | 61.11 Million JPY | -9046.662% |
| Toho Holdings Co., Ltd. | 1476.71 Billion JPY | 99.621% |
| Koa Shoji Holdings Co.,Ltd. | 22.13 Billion JPY | 74.746% |